Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by StockNews.com

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued on Monday.

Several other research firms have also recently issued reports on BPMC. JPMorgan Chase & Co. upped their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Needham & Company LLC reaffirmed a "buy" rating and issued a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. Wedbush reissued an "outperform" rating and set a $128.00 price objective on shares of Blueprint Medicines in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Piper Sandler increased their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines has a consensus rating of "Moderate Buy" and a consensus target price of $125.21.

Remove Ads

Blueprint Medicines Stock Down 1.6 %

Shares of Blueprint Medicines stock traded down $1.42 during trading hours on Monday, reaching $87.12. 908,608 shares of the company were exchanged, compared to its average volume of 1,021,582. The firm has a market cap of $5.57 billion, a PE ratio of -80.67 and a beta of 0.62. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines has a 1 year low of $80.68 and a 1 year high of $121.90. The stock's fifty day moving average is $99.43 and its 200 day moving average is $94.27.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities research analysts forecast that Blueprint Medicines will post -1.28 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jeffrey W. Albers sold 15,000 shares of the business's stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the transaction, the director now owns 157,557 shares of the company's stock, valued at approximately $14,143,891.89. The trade was a 8.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. The trade was a 14.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,427 shares of company stock worth $4,837,801. Insiders own 4.21% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter worth $32,000. R Squared Ltd acquired a new stake in Blueprint Medicines during the fourth quarter worth about $51,000. Covestor Ltd raised its holdings in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 403 shares during the period. Headlands Technologies LLC acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at about $65,000. Finally, Thematics Asset Management acquired a new position in Blueprint Medicines during the fourth quarter valued at approximately $72,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.